Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study
Chen Wang,1 Tieying Sun,1 Yijiang Huang,2 Michael Humphries,3 Lingyan Bai,3 Lilly Li,3 Qian Wang,3 Pearl Kho,4 Roz Firth,4 Peter D'Andrea51Beijing Hospital, Dongcheng District, Beijing, People's Republic of China; 2Hainan Provincial People's Hospital, Xiuying District, Haikou...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-01-01
|
| Series: | International Journal of COPD |
| Online Access: | http://www.dovepress.com/efficacy-and-safety-of-once-daily-glycopyrronium-in-predominantly-chin-peer-reviewed-article-COPD |
| _version_ | 1818956325549244416 |
|---|---|
| author | Wang C Sun T Huang Y Humphries M Bai L Li L Wang Q Kho P Firth R D’Andrea P |
| author_facet | Wang C Sun T Huang Y Humphries M Bai L Li L Wang Q Kho P Firth R D’Andrea P |
| author_sort | Wang C |
| collection | DOAJ |
| description | Chen Wang,1 Tieying Sun,1 Yijiang Huang,2 Michael Humphries,3 Lingyan Bai,3 Lilly Li,3 Qian Wang,3 Pearl Kho,4 Roz Firth,4 Peter D'Andrea51Beijing Hospital, Dongcheng District, Beijing, People's Republic of China; 2Hainan Provincial People's Hospital, Xiuying District, Haikou, People's Republic of China; 3Beijing Novartis Pharma Co Ltd, Zhangjiang Hi-Tech Park, Shanghai, People's Republic of China; 4Novartis Horsham Research Centre, Horsham, West Sussex, UK; 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USABackground: Glycopyrronium is a once-daily (od) long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The GLOW7 study evaluated the efficacy and safety of od glycopyrronium 50 µg in predominantly Chinese patients with moderate-to-severe COPD.Methods: In this 26-week, multi-center, double-blind, placebo-controlled, parallel-group study, men and women 40 years with moderate-to-severe COPD were randomized to glycopyrronium 50 µg od or placebo (2:1). The primary objective was to confirm the significant improvement of trough forced expiratory volume in 1 second (FEV1) following 12 weeks of treatment with glycopyrronium compared with placebo. Secondary objectives included the effect of glycopyrronium on health status (St George's Respiratory Questionnaire), breathlessness (Transition Dyspnea Index), other lung function parameters, rescue medication use, and COPD exacerbations. Safety and tolerability were also evaluated.Results: Of the 460 patients randomized, 459 were included in the full analysis set (glycopyrronium, n=306; placebo, n=154; mean age 64.7 years; mean post-bronchodilator FEV1: 50.8% predicted); 425 (92.4%) completed the study. At Week 12, glycopyrronium significantly improved trough FEV1 with a least square means treatment difference of 141 mL (95% confidence interval 111 mL, 171 mL; P<0.001) compared with placebo. The mean treatment effect of glycopyrronium was greater than the minimum clinically important difference versus placebo in both St George's Respiratory Questionnaire total score (-4.92; P<0.001) and Transition Dyspnea Index focal score (1.0; P<0.001) at week 26. Glycopyrronium reduced the risk of exacerbations in terms of time to first moderate or severe exacerbation by 28% (P=0.153) and rate of moderate or severe COPD exacerbation by 29% (P=0.119) compared with placebo. Incidence of death was 1.3% with glycopyrronium and 0% in placebo during the treatment period. Overall incidence of adverse events (glycopyrronium 43.6%; placebo 47.4%) and serious adverse events (glycopyrronium 5.6%; placebo 9.1%) were similar.Conclusion: In predominantly Chinese patients with moderate-to-severe COPD, od glycopyrronium 50 µg significantly improved lung function, dyspnea, and health status compared with placebo. The safety and tolerability profile of glycopyrronium was comparable to placebo.Keywords: bronchodilation, COPD, dyspnea, exacerbations, glycopyrronium, health status |
| first_indexed | 2024-12-20T10:52:10Z |
| format | Article |
| id | doaj.art-cf2d895d2883480a88ba7970ab516b0a |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-20T10:52:10Z |
| publishDate | 2015-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-cf2d895d2883480a88ba7970ab516b0a2022-12-21T19:43:13ZengDove Medical PressInternational Journal of COPD1178-20052015-01-012015default576819808Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 studyWang CSun THuang YHumphries MBai LLi LWang QKho PFirth RD’Andrea PChen Wang,1 Tieying Sun,1 Yijiang Huang,2 Michael Humphries,3 Lingyan Bai,3 Lilly Li,3 Qian Wang,3 Pearl Kho,4 Roz Firth,4 Peter D'Andrea51Beijing Hospital, Dongcheng District, Beijing, People's Republic of China; 2Hainan Provincial People's Hospital, Xiuying District, Haikou, People's Republic of China; 3Beijing Novartis Pharma Co Ltd, Zhangjiang Hi-Tech Park, Shanghai, People's Republic of China; 4Novartis Horsham Research Centre, Horsham, West Sussex, UK; 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USABackground: Glycopyrronium is a once-daily (od) long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The GLOW7 study evaluated the efficacy and safety of od glycopyrronium 50 µg in predominantly Chinese patients with moderate-to-severe COPD.Methods: In this 26-week, multi-center, double-blind, placebo-controlled, parallel-group study, men and women 40 years with moderate-to-severe COPD were randomized to glycopyrronium 50 µg od or placebo (2:1). The primary objective was to confirm the significant improvement of trough forced expiratory volume in 1 second (FEV1) following 12 weeks of treatment with glycopyrronium compared with placebo. Secondary objectives included the effect of glycopyrronium on health status (St George's Respiratory Questionnaire), breathlessness (Transition Dyspnea Index), other lung function parameters, rescue medication use, and COPD exacerbations. Safety and tolerability were also evaluated.Results: Of the 460 patients randomized, 459 were included in the full analysis set (glycopyrronium, n=306; placebo, n=154; mean age 64.7 years; mean post-bronchodilator FEV1: 50.8% predicted); 425 (92.4%) completed the study. At Week 12, glycopyrronium significantly improved trough FEV1 with a least square means treatment difference of 141 mL (95% confidence interval 111 mL, 171 mL; P<0.001) compared with placebo. The mean treatment effect of glycopyrronium was greater than the minimum clinically important difference versus placebo in both St George's Respiratory Questionnaire total score (-4.92; P<0.001) and Transition Dyspnea Index focal score (1.0; P<0.001) at week 26. Glycopyrronium reduced the risk of exacerbations in terms of time to first moderate or severe exacerbation by 28% (P=0.153) and rate of moderate or severe COPD exacerbation by 29% (P=0.119) compared with placebo. Incidence of death was 1.3% with glycopyrronium and 0% in placebo during the treatment period. Overall incidence of adverse events (glycopyrronium 43.6%; placebo 47.4%) and serious adverse events (glycopyrronium 5.6%; placebo 9.1%) were similar.Conclusion: In predominantly Chinese patients with moderate-to-severe COPD, od glycopyrronium 50 µg significantly improved lung function, dyspnea, and health status compared with placebo. The safety and tolerability profile of glycopyrronium was comparable to placebo.Keywords: bronchodilation, COPD, dyspnea, exacerbations, glycopyrronium, health statushttp://www.dovepress.com/efficacy-and-safety-of-once-daily-glycopyrronium-in-predominantly-chin-peer-reviewed-article-COPD |
| spellingShingle | Wang C Sun T Huang Y Humphries M Bai L Li L Wang Q Kho P Firth R D’Andrea P Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study International Journal of COPD |
| title | Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study |
| title_full | Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study |
| title_fullStr | Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study |
| title_full_unstemmed | Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study |
| title_short | Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study |
| title_sort | efficacy and safety of once daily glycopyrronium in predominantly chinese patients with moderate to severe chronic obstructive pulmonary disease the glow7 study |
| url | http://www.dovepress.com/efficacy-and-safety-of-once-daily-glycopyrronium-in-predominantly-chin-peer-reviewed-article-COPD |
| work_keys_str_mv | AT wangc efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study AT sunt efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study AT huangy efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study AT humphriesm efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study AT bail efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study AT lil efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study AT wangq efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study AT khop efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study AT firthr efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study AT drsquoandreap efficacyandsafetyofoncedailyglycopyrroniuminpredominantlychinesepatientswithmoderatetoseverechronicobstructivepulmonarydiseasetheglow7study |